InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report published on Thursday morning. The brokerage issued a sell rating on the stock.

InspireMD Stock Performance

NYSE:NSPR opened at $2.50 on Thursday. The stock has a fifty day moving average price of $2.38 and a two-hundred day moving average price of $2.50. The stock has a market capitalization of $62.33 million, a price-to-earnings ratio of -3.28 and a beta of 0.95. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.85.

InspireMD (NYSE:NSPR) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06). The business had revenue of $1.51 million during the quarter, compared to analysts’ expectations of $1.38 million. InspireMD had a negative return on equity of 55.12% and a negative net margin of 350.35%. During the same quarter in the previous year, the company posted ($0.53) EPS. On average, analysts predict that InspireMD will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. McKinley Carter Wealth Services Inc. purchased a new position in InspireMD, Inc. (NYSE:NSPR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,000 shares of the company’s stock, valued at approximately $28,000. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.